Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies. Read more
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care. Read more
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke. Read more
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America. Read more
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024. Read more
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more